Division of Adult Reconstructive Surgery, NYU Langone Orthopedics, NYU Langone Health, New York, New York, USA.
Department of Orthopaedic Surgery, Boston Medical Center, Boston, Massachusetts, USA.
Bone Joint J. 2019 Jun;101-B(6):667-674. doi: 10.1302/0301-620X.101B6.BJJ-2018-0723.R3.
With an ageing population of patients who are infected with hepatitis C virus (HCV), the demand for total knee arthroplasty (TKA) in this high-risk group continues to grow. It has previously been shown that HCV infection predisposes to poor outcomes following TKA. However, there is little information about the outcome of TKA in patients with HCV who have been treated successfully. The purpose of this study was to compare the outcomes of TKA in untreated HCV patients and those with HCV who have been successfully treated and have a serologically confirmed remission.
A retrospective review of all patients diagnosed with HCV who underwent primary TKA between November 2011 and April 2018 was conducted. HCV patients were divided into two groups: 1) those whose HCV was cured (HCV-C); and 2) those in whom it was untreated (HCV-UT). All variables including demographics, HCV infection characteristics, surgical details, and postoperative medical and surgical outcomes were evaluated. There were 64 patients (70 TKAs) in the HCV-C group and 63 patients (71 TKAs) in the HCV-UT cohort. The mean age at the time of surgery was 63.0 years (sd 7.5; 44 to 79) in the HCV-C group and 61.7 years (sd 6.9; 47 to 88) in the HCV-UT group.
HCV-UT patients had a significantly longer mean hospital stay (3.4 days 2.9 days; p = 0.04), were more likely to be transferred to the intensive care unit (14.1% 4.3%; p = 0.04), and were significantly more often discharged to a post-acute care facility (39.4% 14.3%; p < 0.01). HCV-UT patients had significantly more postoperative infections (15.5% 4.3%; p = 0.03), surgical complications (21.1% 7.1%; p = 0.02), and revision TKA (12.7% 1.4%; p < 0.01) than HCV-C patients.
The preoperative treatment of HCV can reduce the risk of complications, including prosthetic joint infection and revision TKA. We recommend that HCV treatment regimens should be integrated into the preoperative optimization protocol for this high-risk group of patients. Cite this article: 2019;101-B:667-674.
随着患有丙型肝炎病毒(HCV)的老年患者群体对全膝关节置换术(TKA)的需求不断增长,在这一高危人群中,TKA 的数量持续增加。先前的研究表明,HCV 感染会导致 TKA 后预后不良。然而,关于 HCV 成功治疗且血清学确认缓解的患者行 TKA 的结果信息甚少。本研究旨在比较未治疗 HCV 患者与成功治疗且 HCV 血清学确认缓解的 HCV 患者行 TKA 的结果。
对 2011 年 11 月至 2018 年 4 月期间所有诊断为 HCV 并接受初次 TKA 的患者进行了回顾性研究。将 HCV 患者分为两组:1)HCV 已治愈(HCV-C);2)未治疗(HCV-UT)。评估了所有变量,包括人口统计学、HCV 感染特征、手术细节以及术后医疗和手术结果。HCV-C 组有 64 例患者(70 例 TKA),HCV-UT 组有 63 例患者(71 例 TKA)。HCV-C 组患者的平均手术年龄为 63.0 岁(标准差 7.5;44 至 79),HCV-UT 组为 61.7 岁(标准差 6.9;47 至 88)。
HCV-UT 患者的平均住院时间明显更长(3.4 天比 2.9 天;p = 0.04),更有可能转入重症监护病房(14.1%比 4.3%;p = 0.04),更常转至康复机构(39.4%比 14.3%;p < 0.01)。HCV-UT 患者术后感染(15.5%比 4.3%;p = 0.03)、手术并发症(21.1%比 7.1%;p = 0.02)和翻修 TKA(12.7%比 1.4%;p < 0.01)的发生率明显高于 HCV-C 患者。
HCV 的术前治疗可以降低包括假体关节感染和翻修 TKA 在内的并发症风险。我们建议将 HCV 治疗方案纳入这一高危患者群体的术前优化方案中。